Gamboa Ricardo, Regalado Juan Carlos, Huesca-Gómez Claudia, Posadas-Romero Carlos, Verdejo Paris Juan, Vargas-Alarcón Gilberto, Pérez-Méndez Oscar
Departamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, DF México.
Arch Cardiol Mex. 2008 Oct-Dec;78(4):360-8.
To determine the Paraoxonase-1 (PON1) activity as well as its pheno- and genotypes at position 192 in Mexican subjects with diagnosis of coronary heart disease (CHD).
We determined the PON1-192 polymorphism by PCR-RFLP, and serum PON1 activity, using either paraoxon (PONase activity) or phenylacetate (ARE activity) as substrates, in 155 clinically healthy individuals (control group), and 155 patients with at least one myocardial infarction (CHD group). The biochemical A/B phenotype was determined by the ratio of the NaCI 1 M-stimulated PONase activity divided by the ARE activity.
We found significantly lower PONase and ARE activities in CHD patients as compared to controls (233.1 +/- 102.1 vs. 295.8 +/- 159.1 nmol/min/mL, and 103.1 +/- 33.7 vs 220.2 +/- 120.7 micromol/min/mL, respectively, p<0.05 for both). Allele and genotype frequencies for PON1-192 were similar in CHD patients and healthy controls. Moreover, in the control group, the PON1-192 Q/R genotype did not matched with the A/B phenotype as has been proposed by other studies.
There were important differences in the ARE and PONase activities between Mexican CHD patients and controls, suggesting that PON1 activity could be a good marker of CHD risk, whereas PON1-192 lacks of value to assess such risk.
测定诊断为冠心病(CHD)的墨西哥受试者的对氧磷酶-1(PON1)活性及其192位的表型和基因型。
我们采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)法测定PON1-192多态性,并以对氧磷(PON酶活性)或苯乙酸(ARE活性)为底物,在155名临床健康个体(对照组)和155名至少发生过一次心肌梗死的患者(CHD组)中测定血清PON1活性。通过1M氯化钠刺激的PON酶活性与ARE活性的比值来确定生化A/B表型。
我们发现,与对照组相比,CHD患者的PON酶和ARE活性显著降低(分别为233.1±102.1对295.8±159.1nmol/min/mL,以及103.1±33.7对220.2±120.7μmol/min/mL,两者p均<0.05)。CHD患者和健康对照组中PON1-192的等位基因和基因型频率相似。此外,在对照组中,PON1-192 Q/R基因型与其他研究提出的A/B表型不匹配。
墨西哥CHD患者与对照组之间的ARE和PON酶活性存在重要差异,这表明PON1活性可能是CHD风险的良好标志物,而PON1-192在评估此类风险方面缺乏价值。